04th week of 2014 patent applcation highlights part 46 |
Patent application number | Title | Published |
20140024655 | JANUS KINASE 2 (JAK2) INHIBITOR FOR THE TREATMENT OF LUPUS - The present invention provides a method for treating lupus in a subject, comprising the step of administering to the subject COMPOUND A | 2014-01-23 |
20140024656 | [1,3,4] OXADIAZOLE DERIVATIVE AND APPLICATION THEREOF - The present invention belongs to the medicinal chemistry field, and specifically discloses a [1,3,4]oxadiazole derivative with the structure of general formula (I) and pharmaceutically acceptable salt thereof. The compound can be used to prepare a medicine for preventing or treating a disease of the central nervous system. | 2014-01-23 |
20140024657 | SMALL MOLECULE INHIBITORS OF NECROPTOSIS - The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-α) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I)-(VIII) and by Compounds (1)-(7), (13)-(26), (27)-(33), (48)-(57), and (58)-(70). These necrostatins are shown to inhibit TNF-α induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring necrostatins. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role. | 2014-01-23 |
20140024658 | POLYMORPHIC FORMS OF 1-[4-(5-CYANOINDOL-3-YL)BUTYL]-4-(2-CARBAMOYLBENZOFURAN-5-YL) PIPERAZINE HYDROCHLORIDE - The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypertension, cerebral disorders, chronic pain, acromegaly, hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation. | 2014-01-23 |
20140024659 | N-substituted hetero-bicyclic compounds and derivatives for combating animal pests - The invention relates to N-substituted hetero-bicyclic compounds of formula (I), to the enantiomers, diastereomers and salts thereof and to compositions comprising such compounds. The invention also relates to methods and uses of these N-substituted hetero-bicyclic compounds, and of compositions comprising thereof, for combating and controlling animal pests. Furthermore the invention relates also to pesticidal methods of applying such N-substituted hetero-bicyclic compounds. | 2014-01-23 |
20140024660 | SYNERGISTIC ANTIMICROBIAL COMPOSITION - A synergistic antimicrobial composition comprising: (a) 3-iodo-2-propynyl-butylcarbamate; and (b) flumetsulam. A synergistic antimicrobial composition comprising: (a) 3-iodo-2-propynyl-butylcarbamate; (b) diclosulam. | 2014-01-23 |
20140024661 | FUSED PYRIMIDINES AND SUBSTITUTED QUINAZOLINES AS INHIBITORS OF P97 - A group of fused two ring pyrimidine compounds having a heterocycles substituent at the 2 position and a substituted amine at the 4 position as well as optional aliphatic, functional and/or aromatic components substituted at other positions of the pyrimidine and other ring are disclosed. In addition a group of quinazoline compounds having similar substituents at the 2 and 4 positions as well as at other positions are disclosed. These compounds are inhibitors of the AAA proteasome complex containing p97 and are effective medicinal agents for treatment of diseases associated with p97 bioactivity. | 2014-01-23 |
20140024662 | COMPOUNDS, SCREENS, AND METHODS OF TREATMENT - The present invention features compounds of Formula (I), pharmaceutical compositions, methods of synthesis, and methods for treating diseases and conditions associate with cellular necrosis. Screening assays for identifying compounds useful for treating these conditions are also described. | 2014-01-23 |
20140024663 | ATB(0,+) AMINO ACID TRANSPORTER AS A DRUG TARGET FOR TREATMENT OF ESTROGEN RECEPTOR-POSITIVE BREAST CANCER - The present invention includes inhibitors of the amino acid transporter ATB | 2014-01-23 |
20140024664 | NOVEL ADENINE DERIVATIVES - Compounds of formula (I): | 2014-01-23 |
20140024665 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO - GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: | 2014-01-23 |
20140024666 | PROLYL HYDROXYLASE INHIBITORS - The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) | 2014-01-23 |
20140024667 | FUNGICIDAL COMPOSITIONS - A composition for control of phytopathogenic diseases on useful plants or on propagation material thereof, that, in addition to customary inert formulation adjuvants, comprises as active ingredient a mixture of component (A) and a synergistically effective amount of component (B), wherein
| 2014-01-23 |
20140024668 | FUNGICIDAL COMPOSITIONS - A composition for control of phytopathogenic diseases on useful plants or on propagation material thereof, that, in addition to customary inert formulation adjuvants, comprises as active ingredient a mixture of component (A) and a synergistically effective amount of component (B), wherein | 2014-01-23 |
20140024670 | VETERINARY ANTI-PROLACTIN COMPOSITION FOR RUMINANTS - The present invention relates to a veterinary anti-prolactin composition to be administered to ruminants. Said composition includes at least one anti-prolactin compound which is an agonist for dopamine receptors and which is particularly useful for preventing and/or reducing the harmful effects in ruminants linked to use for a shortened dry period. Said composition is particularly useful for preventing and/or reducing metabolic diseases and/or reproductive disorders when lactation is resumed. The use of the veterinary anti-prolactin composition according to the invention does not adversely affect the milk-producing ability and/or the milk quality of the treated ruminants | 2014-01-23 |
20140024671 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 - Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes. | 2014-01-23 |
20140024672 | AZAINDOLE DERIVATIVES AS CFTR MODULATORS - The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators. | 2014-01-23 |
20140024673 | (2S,3R)-N-(2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)BENZYOFURN-- 2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF - The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms thereof, methods for its preparation, novel intermediates, and methods for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central and autonomic nervous systems. | 2014-01-23 |
20140024674 | TRPM5 INHIBITORS SUPPORT BODY WEIGHT REDUCTION WITHOUT REDUCING FOOD INTAKE - The present invention relates to the field of weight management and the prevention and/or treatment of metabolic disorders. In particular, the present invention provides a composition comprising at least one Trpm5 inhibitor which is effective in the treatment of prevention of metabolic disorders or risk factors thereof, such as overweightness or obesity, without having to reduce food intake below metabolic needs. | 2014-01-23 |
20140024675 | CRYSTALLINE FORMS OF A PROLYL HYDROXYLASE INHIBITOR - The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof. | 2014-01-23 |
20140024676 | CRYSTALLINE FORMS OF A PROLYL HYDROXYLASE INHIBITOR - The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof. | 2014-01-23 |
20140024677 | METHODS FOR INDUCING MITOCHONDRIAL BIOGENESIS - Methods and compositions for inducing mitochondrial biogenesis are provided. In some aspects, methods for the treatment of diseases such as acute kidney disease (AKI) or a muscle wasting disease by administering tomoxetine, nisoxetine, fenoterol, formoterol, or procaterol to an individual are provided. | 2014-01-23 |
20140024678 | STABLE LAQUINIMOD PREPARATIONS - The subject invention provides a pharmaceutical composition comprising N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5- chloro-1-methyl-2-oxoquinoline-3-carboxamide or the salt thereof; a pharmaceutically acceptable carrier; and not more than 0.5% w/w relative to N-ethyl-N-phenyl-1,2,-dihydro-4 -hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide of 2-Chloro-6-(1-ethyl-N-methyl-2-oxoindoline-3-carboxamido) benzoic acid, 1H,3H-spiro[5-chloro- | 2014-01-23 |
20140024679 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES - The present invention provides novel phenylcycloalkylmethylamine derivatives, and methods of preparing phenylcycloalkylmethylamine derivatives. The present invention also provides methods of using phenylcycloalkylmethylamine derivatives and compositions of phenylcycloalkylmethylamine derivatives. The pharmaceutical compositions of the compounds of the present invention can be used for treating and/or preventing obesity and obesity related co-morbid indications and depression and depression related co-morbid indications. | 2014-01-23 |
20140024680 | Insecticidal Arylpyrrolines - The invention relates to novel arylpyrroline compounds of formula (I) | 2014-01-23 |
20140024681 | COMPOUNDS WITH SUPER-ASPIRIN EFFECTS - A compound having the structural formula (I) and pharmaceutically acceptable salt and/or hydrates thereof, (I) wherein Y is an arylester or an C | 2014-01-23 |
20140024682 | PHARMACEUTICAL COMPOUNDS - This invention relates to novel substituted nitrocatechol derivatives, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them. | 2014-01-23 |
20140024683 | CHLORIDE CHANNEL AND CHLORIDE TRANSPORTER MODULATORS FOR THERAPY IN SMOOTH MUSCLE DISEASES - The present invention provides, inter alia, methods and pharmaceutical compositions for preventing, treating, or ameliorating the effects of a disease characterized by altered smooth muscle contractility, such as e.g., asthma and chronic obstructive pulmonary disease. | 2014-01-23 |
20140024684 | BENZOIC ACID SALT OF OTAMIXABAN - The invention relates to a benzoic acid salt of methyl (2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate, and to a benzoic acid salt of methyl (2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate which is in a crystalline form or in at least partially crystalline form, as well as a process for the preparation of the same, methods of using such salt to treat subjects suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa. | 2014-01-23 |
20140024685 | GAMMA-GLUTAMYL TRANSPEPTIDASE INHIBITORS AND METHODS OF USE - Compositions that are effective in inhibiting gamma-glutamyl transpeptidase are disclosed. Methods of producing and using these compositions are also disclosed. | 2014-01-23 |
20140024686 | USE OF GLU-TUBULIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES - Use of glu-tubulin as a biomarker for predicting the response to a compound, preferably resistance of a disease such as cancer in a subject to said compound, wherein the compound is a furazanobenzimidazole compound of general formula (I). | 2014-01-23 |
20140024687 | Combinations of Vascular Disrupting Agents with Inhibitor of Apoptosis Proteins Antagonists - The invention relates to combinations comprising a vascular disrupting agent (VDA) with IAP antagonists, for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of proliferative diseases. | 2014-01-23 |
20140024688 | Potentiated Biocidal Compositions and Methods of Use - The present technology relates to biocidal compositions and methods that contain and utilize at least one biocidal agent and at least one potentiator system wherein the resultant combination has an enhanced biocidal efficacy. The present technology also discloses a rapid screening assay for determining biocidal compositions with enhanced efficacy, e.g., a microbial contact kill time of 5 minutes or less. Further, the present technology provides a method of determining biocidally effective concentrations of biocidal compositions comprising at least one biocidal agent and at least one potentiator system. | 2014-01-23 |
20140024689 | REDUCING FORMALDEHYDE EMISSIONS IN FORMAL-CONTAINING COMPOSITIONS - Method for reducing the formaldehyde emission of a composition containing a formal by adding urea, urea derivatives, amino acids, guanidine or guanidine derivatives. | 2014-01-23 |
20140024690 | Isoxazole Derivatives Useful As Antibacterial Agents - The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections. | 2014-01-23 |
20140024691 | FORMULATIONS OF BENDAMUSTINE - Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C. | 2014-01-23 |
20140024692 | Methods of Treating Neuropathic Pain with Benzimidazole Derivative Agonists of PPARgamma - Embodiments of the invention relate to the treatment of neuropathic pain in mammals. Embodiments of the invention include methods for treating neuropathic pain with benzimidazole derivatives with PPARgamma agonist activity, as well as methods for preparing medicaments used in such treatments of mammalian pain. | 2014-01-23 |
20140024693 | TOPICAL COMPOSITION - A topical composition comprising: fipronil or a pharmaceutically acceptable salt thereof; at least one surfactant and at least one crystallization inhibitor for the treatment and protection of animals which are infested with parasites. | 2014-01-23 |
20140024694 | CHEMICAL COMPOUNDS - This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds. | 2014-01-23 |
20140024695 | METHODS OF TREATING ARTHRITIC CONDITIONS USING (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOI- SOINDOLINE 1,3-DIONE - Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (−) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-α or the inhibition of PDE4. | 2014-01-23 |
20140024696 | ATROPISOMER OF PYRROLE DERIVATIVE - [Object] A prophylactic or therapeutic agent for a cardiovascular disease is provided. | 2014-01-23 |
20140024697 | CO-CRYSTALS OF DULOXETINE AND COX-INHIBITORS FOR THE TREATMENT OF PAIN - The present invention relates to co-crystals of duloxetine and co-crystal formers selected from COX-INHIBITORS, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain. | 2014-01-23 |
20140024698 | METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA - Provided are methods of treatment in subjects having progeroid diseases and related conditions which rely upon LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin. | 2014-01-23 |
20140024699 | COMPOSITIONS AND METHODS FOR INCREASING ERYTHROPOIETIN (EPO) PRODUCTION - The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting one or more EGLN genes, EGLN1, EGLN2 and/or EGLN3 and methods of using such dsRNA compositions to inhibit expression of these genes. | 2014-01-23 |
20140024700 | BLOOD-BORNE MIRNAS AS SURROGATE MARKERS OF DRUG EFFICACY FOR CARDIAC CONDITIONS - The present invention provides methods for evaluating or monitoring the efficacy of a therapeutic intervention for treating a cardiac disorder. Such methods comprise measuring or detecting the level of at least one miRNA in a biological sample from a patient receiving the therapeutic intervention and comparing the level to the level of said at least one miRNA in a control sample, wherein the measured level of said at least one miRNA is indicative of the therapeutic efficacy of the therapeutic intervention. Methods of predicting or assessing the severity or progression of heart failure in a patient by measuring one or more miRNAs in a biological sample from the patient are also disclosed. | 2014-01-23 |
20140024701 | Compositions and Methods for Treating Neurogenic Disorders of the Pelvic Floor - Provided herein are methods for the treatment of bladder dysfunction, including detrusor hyperreflexia and detrusor external sphincter dyssynergia, fecal incontinence, and/or sexual dysfunction in an individual via the use of stably expressed light-responsive opsin proteins capable of selective hyperpolarization or depolarization of the neural cells that innervate the muscles responsible for physiologic functioning of urinary bladder, external urinary sphincter, external anal sphincter, and the male and female genitalia. | 2014-01-23 |
20140024702 | CANCER GENE THERAPY USING NUCLEIC ACIDS ENCODING US28 AND G-PROTEIN - The invention relates to the gene therapeutic treatment of cancer using co-expressed nucleic acids encoding US28 and a G-protein. e.g. GNA-13, or functional fragments thereof, or using nucleic acids encoding fusion polypeptides of US28 and a G-protein or functional fragments thereof. The pharmaceutical compositions according to the invention are used in the treatment of cancer patients to induce apoptosis in tumor cells. | 2014-01-23 |
20140024703 | Novel Block Copolymer, Micelle Preparation, And Anticancer Agent Containing The Same As Active Ingredient - A medicinal preparation is desired which has no harmful side effects such as hypersensitive reaction, heightens the water solubility of a sparingly water-soluble anticancer agent, maintains a high drug concentration in the blood, accumulates a drug in a tumor tissue at a high concentration, heightens the pharmacological effect of the sparingly water-soluble anticancer agent, and diminishes the side effects of the anticancer agent. Provided are: a novel block copolymer which can be a drug carrier having no harmful side effects such as hypersensitive reaction; a micelle preparation in which micelles are formed and which contains a sparingly water-soluble anticancer agent, especially paclitaxel, incorporated in the micelles in an amount necessary for a disease treatment without bonding it to the block copolymer and which can heighten the solubility of the drug in water; and an anticancer agent which comprises the micelle preparation as a medical ingredient, maintains a high concentration in the blood, has more potent drug activity, and is reduced in toxicity. | 2014-01-23 |
20140024704 | PROCESS FOR THE PREPARATION OF OLOPATADINE - A process for the preparation of olopatadine hydrochloride starting from an advanced intermediate. | 2014-01-23 |
20140024705 | MIGRASTATINS AND USES THEREOF - The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | 2014-01-23 |
20140024706 | COMPOSITION COMPRISING SCIRPUSIN A AND SCIRPUSIN B AND ANTI-ADIPOGENESIS/ANTI-OBESITY POTENTIAL THEREOF - Disclosed is a composition comprising scirpusin A and scirpusin B and anti-obesity potential thereof. Also disclosed are methods of inhibiting adipogenesis using a composition comprising scirpusin A and scirpusin B. The present invention also disclosed methods of therapeutically managing obesity in mammals using a composition comprising scirpusin A and scirpusin B. Still further, the present invention also relates to a method of obtaining compositions comprising A. scirpusin A and scirpusin B and B. piceatannol and its dimers scirpusin A and scirpusin B through bioactivity guided fractionation of the rhizomes of | 2014-01-23 |
20140024707 | SMALL MOLECULE ANTAGONISTS OF BACTERIAL QUORUM-SENSING RECEPTORS - A novel small molecule antagonizes two types of acyl homoserine lactone receptors: membrane-bound and cytoplasmic. A focused library of analogs and derivatives of the original antagonist was synthesized. Analog and derivative molecules harbor a range of activities. The novel small molecule and most potent antagonist protects the eukaryote | 2014-01-23 |
20140024708 | URSOLIC ACID SALTS FOR TREATING DIABETES AND OBESITY - The present invention relates to compounds having the following structure: | 2014-01-23 |
20140024709 | METHODS OF USING CYCLOALKYLMETHYLAMINE DERIVATIVES - The present invention provides novel cycloalkylmethylamine derivatives, and methods of preparing cycloalkylmethylamine derivatives. The present invention also provides methods of using cycloalkylmethylamine derivatives and compositions of cycloalkylmethylamine derivatives. The pharmaceutical compositions of the compounds of the present invention can be advantageously used for treating and/or preventing obesity and obesity related co-morbid indications and depression and depression related co-morbid indications. | 2014-01-23 |
20140024710 | 5-AMINOLEVULINIC ACID DERIVATIVES, METHODS FOR THEIR PREPARATION AND USES THEREOF - The present invention provides drug conjugates comprising 5-aminolevulinic acid (ALA), an aldehyde and a carboxylic acid that may function as a histone deacetylase inhibitor (HDACI). These conjugates may serve as co-drugs which release a plurality of active species in vivo. The novel drug conjugates may be used, for the treatment or prevention of cancer in PDT-dependent and/or PDT-independent (nonPDT) treatments, as well as for cosmetic uses. In addition the present invention provides novel uses for both the novel and known compounds. According to some embodiments, the present invention provides drug conjugates (co-drugs) comprising (i) ALA, (ii) an aldehyde and (iii) a carboxylic acid that may function as a histone deacetylase inhibitor (HDACO for the treatment of anemia and/or for the induction of erythropoiesis. | 2014-01-23 |
20140024711 | LOW ALCOHOL ANTIMICROBIAL CLEANSING COMPOSITION - An antimicrobial cleansing composition including (a) 20 to less than 60 wt. % of at least one alcohol selected from ethanol and propanol; (b) 0.5 to 10 wt. % of a surfactant selected from sulfate salt surfactants and amphoteric surfactants. The composition shows effective cleansing and antimicrobial properties. Hence, using this composition, it will no longer be required to provide in hospitals two separate dispensers one for foam soap and one for antimicrobial alcohol-based composition. The antimicrobial cleansing composition can be used for making foam. Also, a dispenser contains the above antimicrobial cleansing composition. | 2014-01-23 |
20140024712 | ACETYL L-CARNITINE FOR THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION OF PAINFUL PERIPHERAL NEUROPATHY IN PATIENTS WITH TYPE 2 DIABETES - Acetyl L-carnitine, or of one of its pharmaceutically acceptable salts, is useful for the prevention of painful peripheral neuropathy in patients suffering from type 2 diabetes, in which symptoms are pain, paraesthesia or hyperaesthesia. The acetyl L-carnitine is administered orally at a dose of at least 3 grams/day. | 2014-01-23 |
20140024713 | USE OF NITRATED LIPIDS FOR TREATMENT OF SIDE EFFECTS OF TOXIC MEDICAL THERAPIES - Methods of treating the side effects of a toxic medical therapy using nitrated lipids are disclosed herein. In particular, the methods comprise the use of nitrated fatty acids or esters thereof to treat side effects, including organ system damage, caused by chemotherapy, radiotherapy, and the administration of other toxic agents. | 2014-01-23 |
20140024714 | ARTIFICIAL OIL BODIES - The present invention relates to artificial oil bodies comprising oleosin (which, as presently defined, also encompasses caleosin, steroleosin and polyoleosin), a surfactant such as a phospholipid, and an oil comprising fatty acids, such as polyunsaturated fatty acids having four or more double bonds. The present invention also relates to methods of preparing said artificial oil bodies. These AOBs may further comprise other molecules such as bioactive molecules, used in a wide variety of products, and are particularly useful for producing oxidatively stable oil-in-water emulsions in the absence of added antioxidants. The present invention further encompasses a method for the partial purification of oleosin from a plant extract. | 2014-01-23 |
20140024715 | METHOD AND KIT FOR ADMIINISTERING GAMMA-GLUTAMYL-D-CYSTEINE FOR THE PREVENTION OF REPERFUSION INJURY FOLLOWING ISCHEMIC STROKE - The present invention provides a method for preventing blood-brain barrier reperfusion injury in a mammalian blood-brain barrier endothelial cell during reperfusion following ischemic stroke comprising administering an effective amount of a γ-glutamyl-D-cysteine antioxidant to the subject and a kit for doing the same. | 2014-01-23 |
20140024716 | Composition Comprising S-Allyl-L-Cysteine as Active Ingredient for Preventing or Treating Gastrointestinal Disorders - A composition including S-allyl-L-cysteine as an active ingredient and having an anti- | 2014-01-23 |
20140024717 | Process For The Preparation Of A Sulfated Derivative Of 3,5-Diiodo-O-[3-Iodophenyl]-L-Tyrosine - The present invention relates to a process for the preparation of the mono sodium salt of the derivative 3,5-diiodo-O-[3-iodo-4-(sulphooxy)phenyl]-L-tyrosine (T3S) by starting from the corresponding phenolic compound, in the presence of chloro-sulfonic acid and dimethylacetamide as a solvent. The so obtained T3S compound may conveniently be isolated in a pure form as a solid in good yields. The present invention further relates to the process for T3S preparation, wherein the starting reagent is T2 and further comprising the formulation of such compound in tablets. Furthermore, the invention discloses non-radioactive immunoassays based on T3S derivatives. | 2014-01-23 |
20140024718 | CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF - The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor. | 2014-01-23 |
20140024719 | Antiseptic compositions, methods and systems - Antiseptic compositions comprising at least one salt of EDTA are disclosed. These compositions have broad spectrum antimicrobial and antifungal activity and they also have anticoagulant properties. The antiseptic compositions have also demonstrated activity in penetrating and breaking down microbial slime, or biofilms. They are safe for human and medical uses and may be used as prophylactic preparations to prevent infection, or to reduce the proliferation of and/or eliminate existing or established infections. | 2014-01-23 |
20140024720 | PHARMACEUTICAL COMPOSITION CONTAINING CYCLOBENZAPRINE SUITABLE TO INTRANASAL ADMINISTRATION - A pharmaceutical composition, containing as active principle cyclobenzaprine hydrochloride, 3-(5H-dibenzo[a,d]cyclo-epten-5-yliden)-N,N-dimethyl-1-propanamine hydrochloride, in form suitable to be administered by itranasal route, is described. Said pharmaceutical composition allows a remarkable absorption rapidity of the active principle, does not undergo the first hepatic passage, has an excellent tolerability with low tonicity formulations and does not show any contraindication in the short period administrations. | 2014-01-23 |
20140024721 | PROCESS TO PRESERVE AQUEOUS PREPARATIONS OF MINERAL MATERIALS, PRESERVED AQUEOUS PREPARATIONS OF MINERAL MATERIALS AND USE OF PRESERVATIVE COMPOUNDS IN AQUEOUS PREPARATIONS OF MINERAL MATERIALS - The present invention refers to a process for preserving an aqueous preparation of mineral material like e.g. calcium carbonate preparations, and to the use of a composition as a preservative in an aqueous preparation of mineral materials. | 2014-01-23 |
20140024722 | Nanostructured Physically-Associating Hydrogels for Injectable, Responsive, and Tough Biomaterials - Described herein are block copolymer conjugates that form double-network hydrogels under appropriate conditions. The conjugates comprise a block of polymer end-group, a block of self-associating peptide or protein, and flexible linkers between the two. Hydrogels comprising the conjugates have the mechanical properties, including elastic modulus and fracture toughness, required for load-bearing applications, while maintaining desirable shear-thinning properties, for example, for injectability. | 2014-01-23 |
20140024723 | COMPOSITION COMPRISING AN ORGANIC LIQUID DILUENT AND A SPECIFIC HYDROXYPROPYL METHYLCELLULOSE - A liquid composition which comprises an organic liquid diluent and at least one hydroxypropyl methylcellulose having 28 to 30 weight percent of methoxyl groups, 7 to 12 weight percent of hydroxypropoxyl groups and a sum of methoxyl groups and hydroxypropoxyl groups of from 38.5 to 42 weight percent is stable over an extended time period. | 2014-01-23 |
20140024724 | Film-Shaped External Preparation Composition - A film-shaped external preparation composition is provided, which is excellent in usability without occurrence of the residues due to a film-forming agent during or after use. The film-shaped external preparation composition comprises a water-soluble cellulose derivative as a primary component of the film; and contains hydroxyethyl urea. Also, it is preferred that the film-shaped external preparation composition is obtained by drying an aqueous solution comprising 40 to 70 mass % of the water-soluble cellulose derivative and 0.01 to 10 mass % of the hydroxyethyl urea. Also, it is preferred that, in the film-shaped external preparation composition, the water-soluble cellulose derivative is hydroxypropyl methylcellulose. | 2014-01-23 |
20140024725 | MODULATORS FOR TRPA1 FOR THE TREATMENT OF ROSACEA - An in vitro method of screening candidate compounds for the preventive or curative treatment of rosacea is described. The method can include determining the capacity of a compound to modulate the expression or activity of the Transient Receptor Potential (TRP) cation channel, subfamily A, member 1(TRPA1), as well as the use of modulators of the expression or activity of this transcription factor for the treatment of rosacea. The method can also include in vitro diagnosis or prognosis of this pathology. | 2014-01-23 |
20140024726 | METHOD AND APPARATUS FOR THE CARBON DIOXIDE BASED METHANOL SYNTHESIS - A plant for the generation of methanol and for providing output power, preferably in the form of heat and/or electric energy. The plant comprises: (1) a water electrolysis facility which can be supplied by electric energy and water and which is designed in order to produce hydrogen gas and oxygen gas. The water electrolysis facility comprises a hydrogen gas outlet and an oxygen gas outlet; (2) a thermal engine with at least one combustion chamber designed for maintaining an oxygen-based combustion process in order to provide output power. The plant further comprises: (1) a gas connection for feeding the oxygen gas from the oxygen gas outlet to the input side of the combustion chamber; (2) a gas connection for feeding a combustion gas composition (CGC) comprising a hydrocarbon gas and carbon dioxide to the input side of the combustion chamber; (3) a gas mixer for providing a gas mixture: and (4) a catalytic reactor for carrying out a catalytic process which processes said gas mixture in order to provide said methanol. | 2014-01-23 |
20140024727 | FISCHER-TROPSCH PROCESS FOR CONVERTING SYNTHESIS GAS TO A LOWER OLEFIN - Effect Fischer-Tropsch synthesis of lower olefins by converting a syngas feedstream at a temperature within a range of from 300° C. to no more than 400° C. using a supported, iron-based catalyst under a total system pressure of at least 2 megapascals with a volumetric ratio of hydrogen to carbon monoxide of at least 3:1 with markedly lower coking rates than attainable at a total system pressure of less than 2 megapascals. | 2014-01-23 |
20140024728 | ANION EXCHANGE POLYMER ELECTROLYTES - Anion exchange polymer electrolytes that include guanidinium functionalized polymers may be used as membranes and binders for electrocatalysts in preparation of anodes for electrochemical cells such as solid alkaline fuel cells. | 2014-01-23 |
20140024729 | POLYMER ELECTROLYTE MEMBRANE CHEMICALLY BONDED WITH IONIC LIQUID AND FUEL CELL USING THE SAME - The present disclosure provides a polymer electrolyte membrane chemically bonded with an ionic liquid. More particularly, the present disclosure provides a polymer electrolyte membrane chemically bonded with an ionic liquid by reacting the ionic liquid with a novel polymer chain terminal. The polymer electrolyte membrane described herein has a high hydrogen ionic conductivity, even in a high-temperature and anhydrous environment. Additionally, the membrane displays electro-chemical and thermal stability. Moreover, the polymer electrolyte membrane may also be applied to a high-temperature and dry-out bio fuel cell. | 2014-01-23 |
20140024730 | COMPOSITION FOR SILICONE RUBBER FOAM, MANUFACTURING METHOD OF SILICONE RUBBER FOAM, AND SILICONE RUBBER FOAM - There are provided a composition for silicone rubber foam, a manufacturing method of a silicone rubber foam, and a silicone rubber foam in which it is possible to control the foaming states. The composition for silicone rubber foam contains: (A) 100 parts by mass of polyorganosiloxane having a degree of polymerization of 4,000 to 10,000 and having two or more alkenyl groups at a content of 0.001 mmol/g or more and less than 0.3 mmol/g; an amount of polyorganohydrogensiloxane having an average of two or more Si-atom-bonded hydrogen atoms so that a molar ratio of the hydrogen atoms to the alkenyl groups in the (A) component is 0.001 to 5; 0.1 to 10 parts by mass of an organic foaming agent with a decomposition temperature of 50 to 250° C.; 5 to 200 parts by mass of silica powder; and a catalyst amount of a platinum-based metal catalyst activated with ultraviolet rays. | 2014-01-23 |
20140024731 | SILICONE COMPOSITION FOR ELASTOMER FOAM - The present relates to novel organopolysiloxane compositions intended to generate an elastomer foam (or silicone foam) with good mechanical properties and low density low density, i.e. less than 0.35 g/cm3 and preferably less than 0.25 g/cm3. | 2014-01-23 |
20140024732 | DOOR MADE OF POLYURETHANE AND METHOD FOR MANUFACTURING THE SAME - A door made of polyurethane, including a door body, the door body including a plurality of integrated plates stacked on one another for supporting. A method for preparing the door includes providing a mold, and spraying a parting agent inside the mold; heating the mold to a temperature of 30-70° C., spraying the parting agent, and placing a plurality of plates or a metal skeleton in the mold; mixing raw materials to obtain a mixture; injecting the mixture into the mold to cover the stacked plates, and curing for 30-90 min; demolding, transferring a product from the mold to a thermostatic chamber for shaping at a constant temperature; trimming uneven edges and surfaces of the product; and spraying a paint on the product. | 2014-01-23 |
20140024733 | PROCESS FOR THE IN SITU PRODUCTION OF POLYETHER POLYOLS BASED ON RENEWABLE MATERIALS AND THEIR USE IN THE PRODUCTION OF FLEXIBLE POLYURETHANE FOAMS - A polyether polyol based on renewable materials is obtained by the in situ production of a polyether from a hydroxyl group-containing vegetable oil, at least one alkylene oxide and a low molecular weight polyol having at least 2 hydroxyl groups. The polyol is produced by introducing the hydroxyl group-containing vegetable oil, a catalyst and an alkylene oxide to a reactor and initiating the alkoxylation reaction. After the alkoxylation reaction has begun but before the reaction has been 20% completed, the low molecular weight polyol having at least 2 hydroxyl groups is continuously introduced into the reactor. After the in situ made polyether polyol product having the desired molecular weight has been formed, the in situ made polyether polyol is removed from the reactor. These polyether polyols are particularly suitable for the production of flexible polyurethane foams. | 2014-01-23 |
20140024734 | HALOGEN-FREE POLY(ALKYLENE PHOSPHATES) - The present invention relates to halogen-free oligomer mixtures of poly(alkylene phosphates), production of these and use as flame retardants, and also to flame-retardant polyurethanes comprising halogen-free oligomer mixtures as flame retardants. | 2014-01-23 |
20140024735 | METHOD FOR PREPARING CROSS-LINKED BITUMEN/POLYMER COMPOSITIONS BY MEANS OF ELECTROMAGNETIC WAVE RADIATION - The disclosure includes a process for preparing cross-linked bitumen/polymer compositions without adding a cross-linking agent, the process comprising contacting at least one bitumen with at least one polymer, and subjecting a mixture of the bitumen and the polymer to electromagnetic wave radiation in a high frequency and/or microwave range. | 2014-01-23 |
20140024736 | POLYMER ARTICLES HAVING CHEMICALLY BONDED AGENTS AND METHODS OF MAKING THE SAME - Modified polymeric articles having modifying agents dispersed within and bonded to an interior region of the article. Methods of modifying polymer materials used to form polymeric articles, and methods of making polymeric articles from polymer particles having modifying agents bonded thereto. | 2014-01-23 |
20140024737 | MILL BASE COMPOSITION AND UV CURABLE INK COMPOSITION COMPRISING SAME - A mill base composition includes a compound comprising a divinyl ester of a dicarboxylic acid, a dispersing agent, and a pigment. The divinyl ester of the carboxylic acid includes from 2 to about 8 carbon atoms. The mill base composition is subjected to milling with milling beads to produce a milled mill base composition that functions as a pigment concentrate that may be added to an ink vehicle to form an ink composition suitable for use in inkjet ink devices. The milled mill base composition is particularly suited for UV curable ink compositions. A UV curable ink composition includes the pigment concentrate, one or more UV curable monomers, and one or more UV initiators. | 2014-01-23 |
20140024738 | Silicone Hydrogel Contact Lenses - Silicone hydrogel contact lenses are described. The lenses are derived from a polymerizable composition including 30-60 unit parts by weight of a hydrophilic monomer(s) having one N-vinyl group, 10 to 50 unit parts by weight of 2-hydroxyethyl methacrylate (HEMA), and a first siloxane monomer component comprising a siloxane monomer of formula (1) as described herein or a siloxane monomer of formula (2) as described herein or a siloxane monomer of formula (3) as described herein or any combination thereof, where the total amount of siloxane monomer(s) present in the polymerizable composition is from 15 to 40 unit parts by weight. Batches of silicone hydrogel contact lenses and methods of making silicone hydrogel contact lenses are also described. | 2014-01-23 |
20140024739 | PASTE-LIKE BONE CEMENT - Paste containing at least one monomer for radical polymerization, at least one polymer that is soluble in said at least one monomer for radical polymerization, and at least one filling agent that is poorly soluble or insoluble in said at least one monomer for radical polymerization, wherein the filling agent is a particulate inorganic filling agent possessing a BET surface of at least 40 m | 2014-01-23 |
20140024740 | CARPET BACKING COMPOSITIONS PREPARED FROM RECYCLED PAINT - Described herein are carpet backing compositions prepared with paint. These compositions have (a) one or more first polymers, (b) one or more second polymers derived from a latex paint, (c) a filler, (d) a froth aid, and (e) a thickener. The compositions described herein solve several technical problems which have heretofore been inadequately addressed. The compositions described herein accept the required filler loading, can be applied easily without interference by paint components, have high solids contents, and dry or cure quickly. Methods for making the compositions and articles comprising the compositions are also described herein. | 2014-01-23 |
20140024741 | HIGH-LATENCY HARDENERS FOR EPOXY RESINS - The present invention relates to novel high-latency liquid hardeners for hardening of curable polymer resins, especially epoxy resins, and to epoxy resin compositions comprising liquid hardeners for the production of fibre composite materials. | 2014-01-23 |
20140024742 | COATING COMPOSITION, AND A PROCESS FOR PRODUCING THE SAME - The present invention provides a coating composition, a process for producing the same, one or more coating layers derived therefrom, and articles comprising one or more such coating layers. The coating composition according to the present invention comprises: (a) from 10 to 90 percent by weight of an aqueous, high-solid, solvent-free alkyd dispersion comprising: (i) from 40 to 70 percent by weight of one or more alkyds based on the total weight of the dispersion, wherein each said one or more alkyds has an acid value of less than 20 and a molecular weight (Mn) in the range of greater than 1000 Dalton; (ii) from less than 10 percent by weight of one or more surfactants, based on the total weight of the dispersion; and (iii) from 30 to 55 percent by weight of water, based on the total weight of the dispersion; wherein said aqueous, high-solid, solvent-free alkyd dispersion has an average particle size diameter in the range of from 0.05 to 5 μm; (b) from 10 to 90 one or more second dispersions, one or more second emulsions, or combinations thereof; wherein said coating composition has a solid content of in the range of from 25 to 65 percent by weight of solid content, based on the total weight of the coating composition, and the coating composition has a pH in the range of from 7 to 11, and wherein the coating composition has a volume average particle size in the range of from 0.03 to 5 μm, and wherein the coating composition has a viscosity in the range of from 100 to 10,000 cP. | 2014-01-23 |
20140024743 | Aqueous Coating Composition - An aqueous coating composition contains a binder combination A) including A1) and A2) wherein A1) contains 60 to 90 wt % of a water-dilutable (meth)acrylate copolymer containing a) 10 to 80 wt % of a reaction product of a monoepoxyester and an unsaturated acid functional monomer, b) 0 to 40 wt % of a hydroxyl functional unsaturated monomer that is different from component a), c) 1 to 8 wt % of an unsaturated acid functional monomer, and d) 0 to 70 wt % of another polymerisable unsaturated monomer, and A2) contains 10 to 40 wt % of a water-dilutable epoxyester resin, and the aqueous coating composition further contains B) an isocyanate compound as a cross-linking agent. | 2014-01-23 |
20140024744 | HIGH HEAT RESISTANT COMPOSITION - The invention relates to a composition that can be used as a coating and that can protect a substrate coated with this composition from high heat. The composition comprises: a polysulfide, an epoxy resin, a compound selected from compounds having a secondary and/or a tertiary amine group, and compounds having an amide group, a polysiloxane, and fibres. | 2014-01-23 |
20140024745 | TYRE, THE TREAD OF WHICH COMPRISES A POLY(ALKYLENE ESTER) RESIN - A tyre, the tread of which comprises a rubber composition comprising at least: a diene elastomer; from 100 to 150 phr of a reinforcing inorganic filler; a poly(alkylene ester) thermoplastic resin; a plasticizing system comprising: according to a content A of between 5 and 60 phr, a hydrocarbon resin exhibiting a Tg of greater than 20° C.; according to a content B of between 5 and 60 phr, a plasticizer which is liquid at 20° C., the Tg of which is less than −20° C.; and it being understood that A+B is greater than 40 phr. The use of a poly(alkylene ester) resin, combined in particular with high contents of filler and plasticizers, makes it possible to improve the stiffness of the tread and thus the road behaviour of the tyre, without affecting the hysteresis and thus the rolling resistance. | 2014-01-23 |
20140024746 | CELLULOSIC INCLUSION THERMOPLASTIC COMPOSITION AND MOLDING THEREOF - A cellulosic inclusion-thermoplastic composition that includes cellulosic inclusions and a thermoplastic polyolefin that forms a matrix in which the cellulosic inclusions are dispersed. A maleated polymer and a polar thermoplastic polymer resin of a polyamide or polyester are provided to improve adhesion between the cellulosic inclusions and the thermoplastic polyolefin. The polar thermoplastic polymer resin is characterized by a melting temperature greater than that of the thermoplastic polyolefin. The composition as provided has increased break tensile strength relative to a composition devoid of the polar thermoplastic polymer resin but otherwise is unchanged. The break tensile is measured at 23° Celsius and at an elongation rate of 50 millimeters per minute. | 2014-01-23 |
20140024747 | System and Method for High Throughput Preparation of Rubber-Modified Asphalt Cement - This invention encompasses rubber modified asphalt cement compositions, as well as systems, apparatuses, methods for preparing, as well as methods for using rubber-modified asphalt cement compositions. | 2014-01-23 |
20140024748 | USE OF POLYHYDROXYALKANOATES AS ADDITIVES IN COATING COMPOSITIONS - The present invention relates to the use of polyhydroxyalkanoates as additives in coating compositions and also to coating compositions comprising polyhydroxylalkanoates as matting agents. The present invention further relates to coatings produced with the coating composition of the invention, comprising polyhydroxyalkanoates, on a substrate. | 2014-01-23 |
20140024749 | Polymer and Compositions Thereof - The invention relates to a composition containing a polymer obtained by polymerising (1) a mono-vinyl monomer with one or more carboxylic acid groups to form a polymer with at least 2 to 200, or 5 to 150, or 10 to 100, or 15 to 50 repeat units, and (2) reacting the polymer of (1) with a primary hydrocarbyl amine and polyoxyalkylene primary amine (typically polyetheramine). The invention further relates to a composition containing a particulate solid, a liquid medium, and the polymer. The invention further relates to the use of the polymer as a dispersant. | 2014-01-23 |
20140024750 | Polymer Composition for Microelectronic Assembly - Embodiments in accordance with the present invention encompass polymer compositions that act as both a tack agent and a fluxing agent for the assembly of microelectronic components onto a variety of substrate materials. Such polymer compositions embodiments encompass a sacrificial polymer, a carrier solvent, a thermal acid generator and, optionally, formic acid. | 2014-01-23 |
20140024751 | MATERIAL FOR ALIGNMENT LAYER OF LIQUID CRYSTAL DISPLAY - The present invention provides a material for alignment layer of liquid crystal display, which includes a solvent and a polymer dissolved in the solvent. The polymer includes a backbone and a first side chain linked to the backbone. The first side chain has a stronger lateral dipole moment. The material for alignment layer of liquid crystal display is characterized in that a first side chain that contains both a flexible chain segment and rigid chain segment is linked to the backbone of the polymer and the first side chain has a stronger lateral dipole moment, making it taking a rotation or tilting motion under the application of an electric field so as to effect alignment of the liquid crystal molecules in the pre-tilt angle. | 2014-01-23 |
20140024752 | LIQUID CRYSTAL ALIGNMENT AGENT, AND LIQUID CRYSTAL ALIGNMENT FILM AND LIQUID CRYSTAL DISPLAY ELEMENT FORMED FROM THE LIQUID ALIGNMENT AGENT - A liquid crystal alignment agent includes a polymer composition obtained by subjecting a diamine component and a tetracarboxylic dianhydride component to a reaction, a solvent, and a hydroxyl compound. Preferably, the hydroxyl compound has a weight average molecular weight ranging from 300 to 1,000,000. A liquid crystal alignment film formed from the liquid crystal alignment agent and a liquid crystal display element including the liquid crystal alignment film are also disclosed. | 2014-01-23 |
20140024753 | LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM AND LIQUID CRYSTAL DISPLAY ELEMENT - A liquid crystal alignment agent contains a polymer and a solvent. The polymer is obtained by subjecting a mixture including a tetracarboxylic dianhydride component and a diamine component to a reaction. The diamine component includes a diamine compound of formula (I) defined herein, a benzimidazole-group-containing diamine compound, and a diamine compound other than the diamine compound of formula (I) and the benzimidazole-group-containing diamine compound. The liquid crystal alignment agent has superior processing stability, and a liquid crystal display element made from the aforesaid liquid crystal alignment agent has superior reliability. | 2014-01-23 |
20140024754 | HEPTYL ESTERS OF FURAN DICARBOXYLIC ACID AS SOFTENERS - The invention relates to the use of heptyl esters of furan dicarboxylic acid as softeners. | 2014-01-23 |
20140024755 | METHOD FOR DEFOAMING A VINYL CHLORIDE RESIN SLURRY - Disclosed is a method for defoaming a vinyl chloride resin slurry. The agent of the present invention may prevent generation of Fish eyes and deteriorate in production efficiency caused by slurry foams without inhibiting inherent transparency of vinyl chloride resins, in the process of preparing the vinyl chloride resins by polymerizing a monomer mixture containing vinyl chloride as a main component in a polymerization reactor. | 2014-01-23 |